XML 10 R2.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 5,918 $ 7,935
Short-term investments 12,039 10,734
Prepaid clinical trial expenses 352 748
Other prepaid expenses and current assets 655 248
Total current assets 18,964 19,665
Property and equipment, net 105 119
Other assets 11 10
Total assets 19,080 19,794
Current liabilities:    
Accounts payable 1,912 1,998
Accrued clinical trial costs 670 820
Accrued expenses 895 866
Total current liabilities 3,477 3,684
Promissory note 8,500 0
Warrant liability 1,000 1,700
Total liabilities 12,977 5,384
Commitments and contingencies (Note 8)
Stockholders' equity    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; no shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 0 0
Common stock, $0.0001 par value; 500,000,000 shares authorized at June 30, 2025 and December 31, 2024, respectively; 13,971,990 and 13,481,917, issued and outstanding at June 30, 2025 and December 31, 2024, respectively 4 4
Additional paid-in capital 176,865 174,166
Accumulated deficit (170,762) (159,764)
Accumulated other comprehensive (loss) income (4) 4
Total stockholders' equity 6,103 14,410
Total liabilities and stockholders' equity $ 19,080 $ 19,794